Parental awareness and attitudes towards prevention of respiratory syncytial virus in infants and young children in Australia

Charlie Holland (1), Megan Baker (1), Amber Bates (2), Catherine Hughes (3), Peter C Richmond (4,5,6,7), Samantha Carlson (1,8) and Hannah C Moore (1,9)

- Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia
- 2. Tiny Sparks Western Australia
- 3. The Immunisation Foundation of Australia
- 4. Discipline of Paediatrics, School of Medicine, University of Western Australia
- 5. Director, Vaccine Trials Group, Wesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute
- 6. Perth Children's Hospital, Child and Adolescent Health Service
- 7. Department of Immunology, Perth Children's Hospital, Child and Adolescent Health Service
- 8. School of Social Sciences, The University of Western Australia, Perth, Western Australia, Australia
- 9. School of Population Health, Curtin University, Perth, Western Australia, Australia

Short title: RSV parental awareness

Corresponding author: Charlie Holland, Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia. Tel +610415537035. Email Charlie.holland@telethonkids.org.au.

Abstract

Aims: To assess parental awareness of respiratory syncytial virus (RSV) and the level of acceptance of future RSV prevention strategies. Methods: A cross-sectional online survey was implemented targeting "future" and "current" parents of children aged ≤5 years in Australia. Results: From 1,992 eligible participants, two non-mutually exclusive subgroups were formed; "current" parents (N=1931) and "pregnant/planning" parents (N=464; 403 also "current" parents; 61 "future" parents). Participants were predominantly (86.6%) aged 25-39 years and 68.5% with university education. The majority (89.6% current; 78.7% future) had heard of RSV. Of those, 64.2% (current) and 50.0% (future) were aware that pneumonia is associated with RSV; 71.8% (current) and 52.1% (future) were aware that bronchiolitis is associated. In multivariable logistic regression analyses, Australian-born parents (aOR=2.47 [95%CI:1.48-4.12]), living in the Eastern States (e.g., New South Wales: aOR=6.15 [95%CI:2.10-18.04]), with a university level education (aOR=2.61 [95%CI:1.38-4.94]) and being a current parent (aOR=12.26 [95%CI:2.82-53.28]) were associated with higher RSV awareness. There was a high level of acceptance for maternal vaccines (future: 79.3%) and infant immunisation (all: 81.7%). Conclusion: While RSV awareness and immunisation acceptance was high, there was limited knowledge of severity of RSV, especially in future parents. Education campaigns need to be developed to increase RSV knowledge.

Key notes

The success of RSV immunisation programs is dependent on the community having sufficient disease awareness and acceptance of new immunisation strategies. Majority of parents in the study had heard of RSV, however lacked awareness on associated conditions and disease severity, particularly future parents. Education and awareness campaigns are required to inform parents about RSV and future immunisations; there is a critical opportunity to increase awareness prior to immunisation arrival.

Introduction

Respiratory syncytial virus (RSV) is the predominant cause of respiratory infections and is most prevalent in infants and young children.¹ RSV causes 33.0 million annual cases globally, 3.6 million hospitalisations and 101,400 deaths in children aged less than 5 years.² RSV is the leading cause of bronchiolitis and pneumonia, and is associated with later respiratory morbidity including asthma and long-term wheezing.^{3,4,5} Infants at risk of developing severe RSV infections include those <6 months or born prematurely (<37 weeks gestation), and children of all ages with comorbidities.^{6,7} RSV causes seasonal epidemics, often peaking in the winter months,⁸ but there has been some variability to the typical seasonal pattern since COVID-19.^{9,10} Currently, Palivizumab is the only licensed RSV prevention product,¹¹ available to high-risk infants and requires costly monthly injections.^{12,13}

Since 2019, the World Health Organization (WHO) has recognised RSV as a priority target for prevention through vaccination. He RSV vaccination landscape is rapidly progressing, with >30 maternal vaccine and single dose long-acting monoclonal antibody (mAb) candidates in clinical trials. Whilst no vaccine candidates have yet been approved for use in Australia, a single dose long-acting mAb has been approved in Europe and the United Kingdom. Hous, with the imminent arrival of RSV immunisation strategies in Australia, it is critical to understand what factors may contribute to uptake of these products. A Melbourne based study in 2019 found 83.0% of pregnant mothers had never heard of RSV before, though after receiving information, 77.0% were very likely to accept an RSV maternal vaccine. Similar findings were found in a recent global study. These findings suggest that maternal vaccine and mAb uptake may rely on parents having sufficient awareness and knowledge of RSV. There is currently a lack of contemporary data on RSV community awareness in Australia. We aimed to assess parent awareness of RSV and the level of acceptance of RSV prevention strategies.

Methods

Study design

We conducted an Australian wide cross-sectional survey from 15th July to 27th August 2022. Eligible participants were those aged ≥18 years, residing in Australia, could read and understand English and were either currently pregnant, planning to become pregnant in the next 6 months, a partner of a pregnant person, and/or were caring for at least one child aged ≤5 years. Eligible participants were divided into two non-mutually exclusive subgroups; 1) pregnant/planning, and 2) current parent. Participants who only fit into the pregnancy/planning subgroup formed an additional subgroup "future" parents which was used for analysis to compare future and current parents.

Survey Instrument

Survey items were derived from previously published studies on childhood and pregnancy vaccine attitudes, 17,19 as well as the research team's expertise on RSV disease and immunisation strategies. Items were reviewed by our consumer representative for relevance to our intended population. The survey was refined through user testing by the research team. The final survey included 47 items focusing on awareness of childhood respiratory illnesses, awareness of RSV and willingness to accept and potentially pay for RSV immunisations strategies. The pregnant/planning subgroup were questioned on their acceptance towards RSV maternal immunisations and what source they refer to for information regarding infectious diseases and vaccines in pregnancy. The current parent subgroup were questioned on their acceptance towards RSV childhood immunisation and what information sources they refer to for infectious diseases and childhood vaccines. Participants fitting into both subgroups were questioned on both immunisation strategies and information sources. Following these questions, participants were provided with information on RSV and then asked the same questions on immunisation acceptance to determine if there were any changes to their responses. Participants were asked an open-ended question regarding what information they would need to decide on RSV prevention products.

Recruitment

Online recruitment occurred through two avenues: promotion through community networks (Immunisation Foundation of Australia, a community-member network that advocates for immunisations; Tiny Sparks WA, a not-for-profit organisation for high-risk pregnancies and sick or premature infants) and targeted advertising on social media (Facebook, Instagram) facilitated by the digital team at Telethon Kids Institute. Following eligibility screening and consent, participants were directed to the web-based survey on REDCap.

5

Statistical analysis

Descriptive statistics including frequencies with 95% confidence intervals (CI) were used for categorial responses, with comparison of proportions using chi-squared tests. To assess the predictors of RSV awareness, we used multivariable logistic regression with RSV awareness as a binary outcome (yes/no) with demographic and questionnaire responses as possible covariates. We present odds ratios (ORs) with 95% CI. Factors with a p-value of <0.2 in univariate analysis were included in a multivariable model. To assess for selection bias in the survey sample, the socio-demographic characteristics of respondents were compared to Australia's general population using Australian Bureau of Statistics (ABS) data. STATA version 17 was used for all analyses. Openended question data were thematically analysed using the Braun and Clarke method²⁰ to describe themes. Two researchers (CH and MB) independently applied initial codes following data familiarisation. Initial codes were then compared and manually collated into themes until consensus between both researchers was reached. Ethics approval was obtained by the University of Western Australia Human Research Ethics Committee (ET000182).

Results

From a 6-week period, 1,992 eligible participants were recruited; 464 formed the pregnant/planning subgroup (61 participants who fit only into this subgroup were considered "future parents") and 1,931 formed the current parent subgroup (403 participants fit into both subgroups). The majority of participants were aged 25-39 years

Most participants (>80.0%) in the future and current parent subgroups had heard of all the childhood respiratory illnesses and pathogens, aside from *Bordetella pertussis* where only half of participants indicated they were aware (50.8% future: 56.3% current; Table 2). This was despite the majority of participants having heard of whooping cough (95.1% future: 95.0% current). Over three-quarters (78.7%) of future and 89.6% of current parents reported awareness of RSV. Notably, awareness was lower in the future parent subgroup compared to the current parent subgroup for all conditions; but only reached statistical significance for RSV, bronchiolitis and pneumonia (Table 2). Pneumonia and whooping cough caused the highest level of concern (Figure 1).

Respondents with RSV awareness had limited knowledge of associated RSV conditions (Supplementary Table 1). Only half (50.0%) of future parents and 64.2% of current parents were aware that pneumonia is associated with RSV; and 52.1% of future parents and 71.8% of current parents were aware that bronchiolitis is associated. Parents also demonstrated a low level of understanding that asthma (31.3% future; 30.6% current) and wheezing (56.3% future; 74.7% current) can be associated with RSV. From 1,931 current parents, 712 (36.9%) indicated that at least one of their children aged ≤5 years had been infected with RSV before; of those, 304 (42.3%) reported their child required hospitalisation.

Univariate logistic regression analysis suggested being born in Australia, speaking English as a primary language, living in the eastern states, having a university degree,

Prior to being provided information on RSV, all pregnant/planning parents (including those with and without prior children) had a high level of acceptance (79.7%, n=370) towards receiving a maternal RSV vaccine. Similarly, the acceptance of a maternal vaccine was high in the future parent group (including only those without prior children; 86.9%, n=53). Overall, future (93.4%) and current parents (81.4%) had a high level of acceptance towards an infant RSV immunisation prior to information being provided. There were no participants in the future parent subgroup and only 20 (1.0%) participants in the current parent subgroup that were not accepting of infant immunisation. Future parents who were accepting of both immunisation strategies (N=57) were asked on their immunisation strategy preference; majority accepted the maternal vaccine in combination or isolation of an infant immunisation as opposed to only an infant immunisation (both: 49.1%, maternal vaccine: 38.6%, infant immunisation: 3.5%).

Prior to completing the survey, few 'future' parents were unaware of RSV (10/61), but 90% (9/10) of these were willing to accept a maternal vaccine prior to learning about RSV, which increased to 100% after receiving information. Similarly, 97 of 1,931 'current' parents were unaware of RSV prior to participation, however, 78.4% (76/97) were accepting of infant immunisation prior to learning about RSV, which increased to 85.6% (83/97) after receiving information.

The amount current and future parents were willing to pay for immunisations did not significantly differ before or after being provided with information on RSV. However, the

Participants in the pregnant/planning subgroup identified their top 3 sources for infectious disease and vaccine information as their midwife (32.1%), google search (26.3%) and obstetrician (14.0%). Of those who selected google search, nearly half (46.0%) further indicated Government websites, 28.3% hospital websites, 12.4% science articles and 9.7% special health websites. Participants in the current parent subgroup identified their top 3 sources for information as google search (34.6%), their nurse (21.0%) and midwife (13.6%). Similar, most common google searches were for special health websites (44.4%), hospital websites (40.7%), Government websites (7.8%) or science articles (6.1%).

From 1,538 participants responding to the open-ended question regarding information needs for immunisation decision-making, three key themes were identified: defining RSV, prevention product information, and research and evidence (having peer-reviewed scientific evidence). Participants highlighted they need further information on RSV before accepting immunisations, including understanding the virus, symptoms, complications, severity, likelihood of infection and age groups most at risk.

Respondents indicated that they'd also require information on the specific RSV prevention product, including benefits and risks, effectiveness, number and frequency of doses, management of side effects, and ideal age/s of administration. Some respondents indicated the need for approval from relevant government bodies and medical authorities, results and safety data from clinical trials and information from peer-reviewed sources.

Discussion

We present here contemporary data on the parental awareness of RSV and acceptability of RSV immunisation strategies, likely to be available in Australia in the next 1-2 years. Current and future parents had a high level of awareness of most common childhood respiratory illnesses, including RSV. Notably, current parents were

more aware of RSV compared to future parents. Though most participants had heard of RSV, there was a lack of awareness on associated conditions, especially among future parents. Indeed, the strongest independent factor of RSV awareness was being a current parent of a child aged ≤5 years.

9

Contrary to our findings, an earlier study in 2019 in Australia found majority of participants (83.0%) had never heard of RSV.¹⁷ However, our results are similar to that observed in a recent global study; majority of participants were only aware of the name of the virus and experienced parents had a higher level of awareness compared to new parents. 18 The global study shared other similar observations; participants were more concerned about pneumonia than RSV perse and were more concerned about RSV than they were about bronchiolitis. 18 There are several factors that are likely to contribute to the high level of awareness of RSV observed in our study. Firstly, our survey was administered at a time of peak RSV activity in 2022, especially in New South Wales (1000 cases recorded in the third quarter of 2022)²² and Victoria (11,291 cases in the same period).²² Secondly, there was increased media coverage on RSV in Australia due to the heightened number of cases²³, and thirdly, our survey demographic was a highly educated population. Regardless of the high proportion of participants who were aware of RSV, the knowledge of key associated conditions including pneumonia and bronchiolitis was significantly low. This suggests the need for more education amongst Australian parents, particularly first-time parents, on disease severity of RSV in children.

In our study, parents had a high level of acceptance towards both RSV immunisation strategies prior to receiving information. Additionally, parents who had never heard of RSV became more accepting of immunisation once they received information. This demonstrates the importance of adequate knowledge of RSV as a key contributing factor towards acceptability of RSV immunisation. Furthermore, the median price future parents were willing to pay for RSV childhood immunisation increased by A\$6 following receiving information. This conjecture was supported by both the Melbourne¹⁷ and global¹⁸ study. Both current and future parents referred to reputable and reliable sources for information regarding infectious diseases and vaccines. Furthermore, the

qualitative findings in the study indicate that parents require information on RSV, as well as on associated prevention products and evidence supporting their use, to help in decision-making for RSV immunisations. Thus, when RSV immunisation strategies are implemented in Australia, it is vital that parents are equipped with information on the product and the disease. Such materials should particularly be targeted towards future parents; there is evidently a critical time and opportunity to inform new parents about RSV.

A major strength of our study was the large sample size we were able to attain through online recruitment. Facebook was the social media platform that reached the highest level of engagement with 159,624 impressions, 84 comments, 37 shares and 128 reactions. The use of a broad message summarising the purpose of the study, an engaging image (e.g., infant or pregnant mother receiving an immunisation), and the survey accessible online, were important factors to the successful participant recruitment. A further strength of our study was the co-designing of questions with community members including question wording and how to make the survey advertising appeal to the target audience. The result of community involvement in our research produced a simple, inclusive and easy to understand survey.

Despite these strengths, our study was not without limitations. The narrow demographic range of participants significantly reduced the generalisability of the results to the overall Australian population.²¹ People who are highly educated, spoke English, and from a middle to upper socioeconomic class were over-represented in the data. For this reason, there may have been an overestimation of the level of RSV awareness and acceptance of future immunisations. Another limitation of the study was that the online promotion of the survey was targeted to those engaged online with organisations involved in awareness of childhood respiratory conditions. This may have increased selection bias in the study as there is an assumption that participants who are engaged online with such organisations would have a heightened awareness about childhood respiratory conditions.

and targeting those who are at higher risk of severe outcomes associated with RSV. This could include groups with low levels of education, high unemployment rates, those from rural or remote Australia, Aboriginal and/or Torres Strait Islander families, culturally and linguistically diverse families, premature infants, and children with comorbidities. We are planning on conducting culturally appropriate research targeted towards and working alongside Aboriginal and/or Torres Strait Islander families.

Conclusion

With Australia expected to follow Europe and the UK with licensure of mAb and expected licensure of a RSV maternal vaccine, more awareness of RSV among the community is required. Education and awareness campaigns would be most beneficial prior to childbirth, particularly among first time parents.

Acknowledgements

The study investigators would like to acknowledge the community members and participants who contributed to the study, as well as Dr Monica Rikard-Bell who provided us with the survey questionnaire that was used in a COVID-19 vaccine acceptance study¹⁹ that we modified for our study. This study was funded through a Wesfarmers Centre of Vaccine and Infectious Diseases Seed Grant at the Telethon Kids Institute. HCM is funded by a Stan Perron Charitable Foundation Fellowship and a Future Health Research and Innovation Fund through the WA Near-miss Awards program.

Conflicts of Interest

Associate Professor Richmond and Associate Professor Moore is in receipt of research funds from Merck Sharp & Dohme (Australia) Pty Ltd and Sanofi-Aventis Australia Pty Ltd (unrelated to the work presented in this paper). Associate Professor Richmond and

Associate Professor Moore has also received institutional honoraria for participating in advisory committees (Pfizer, Merck Sharp & Dohme, EvoHealth) also unrelated to the work presented in this paper.

12

Author contributions

Holland C had primary responsibility for survey development, statistical analysis (quantitative) and writing the manuscript.

Baker M had responsibility of project management, statistical analysis (qualitative) and editing/reviewing the manuscript.

Bates A and Hughes C had investigator roles and responsibility of providing feedback on the survey questionnaire and design and editing/reviewing the manuscript.

Dr Carlson and A.Prof Moore HC had primary responsibility of project conceptualisation, protocol development, methodology development, supervision and editing/reviewing the manuscript.

A.Prof Richmond supervised the overall project.

- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. *Lancet*. 2010;375(9725):1545-1555. doi:10.1016/S0140-6736(10)60206-1
- 2. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*. 2022;399(10340):2047-2064. doi:10.1016/S0140-6736(22)00478-0
- 3. Smith DK, Seales S, Budzik C. Respiratory Syncytial Virus Bronchiolitis in Children. *Am Fam Physician*. 2017;95(2):94-99.
- Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study [published correction appears in Lancet. 2019 Aug 31;394(10200):736]. *Lancet*. 2019;394(10200):757-779. doi:10.1016/S0140-6736(19)30721-4
- 5. Australian Institute of Health and Welfare Content Team. Australia's Children. *Australian Government: Australian Institute of Health and Welfare*. Updated February 25, 2022. Accessed April 1, 2022. https://www.aihw.gov.au/reports/children-youth/australias-children/contents/health/asthma-prevalence-children
- 6. Azzari C, Baraldi E, Bonanni P, et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. *Ital J Pediatr*. 2021;47(1):198. Published 2021 Oct 2. doi:10.1186/s13052-021-01148-8
- 7. Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to Respiratory Syncytial Virus. Burden and Risk Factors. *Am J Respir Crit Care Med*. 2017;195(1):96-103. doi:10.1164/rccm.201603-0658OC
- 8. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. *J Infect Dis.* 2018;217(9):1356-1364. doi:10.1093/infdis/jiy056
- Foley DA, Phuong LK, Peplinski J, et al. Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia. *Arch Dis Child*. 2022;107(3):e7. doi:10.1136/archdischild-2021-322507
- Eden JS, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. *Nat Commun.* 2022;13(1):2884. Published 2022 May 24. doi:10.1038/s41467-022-30485-3
- Navarro Alonso JA, Bont LJ, Bozzola E, et al. RSV: perspectives to strengthen the need for protection in all infants. *Emerg Themes Epidemiol*. 2021;18(1):15. Published 2021 Oct 21. doi:10.1186/s12982-021-00104-5
- 12. Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis. *Pediatr Infect Dis J.* 2017;36(8):699-704. doi:10.1097/INF.000000000001533
- 13. Samson L. Prevention of respiratory syncytial virus infection. *Paediatr Child Health*. 2009;14(8):521-532. doi:10.1093/pch/14.8.521

- World Health Organization. WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines. World Health Organization. Updated January 1, 2017. Accessed April 1, 2022. https://www.who.int/publications/i/item/WHO-IVB-17.11
- 15. PATH. RSV vaccine and mAB snapshot. *PATH*. Updated June 2, 2023. Accessed June 5, 2023. https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/
- 16. Precision Vaccinations Content Creation Staff. Beyfortus (Nirsevimab) RSV Antibody 2023. *Precision Vaccinations*. Updated May 2, 2022. Accessed March 28, 2023. https://www.precisionvaccinations.com/vaccines/beyfortus-nirsevimab-rsv-antibody-2023
- 17. Giles ML, Buttery J, Davey MA, Wallace E. Pregnant women's knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines. *Vaccine*. 2019;37(44):6743-6749. doi:10.1016/j.vaccine.2019.08.084
- 18. Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. *Expert Rev Vaccines*. 2022;21(10):1523-1531. doi:10.1080/14760584.2022.2108799
- Rikard-Bell M, Elhindi J, Lam J, et al. COVID-19 vaccine acceptance among pregnant women and the reasons for hesitancy: A multi-centre cross-sectional survey. Aust N Z J Obstet Gynaecol. 2023;63(3):335-343. doi:10.1111/ajo.13622
- 20. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol.* 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa
- 21. Australian Bureau of Statistics. Snapshot of Australia. *ABS*. Updated June 28, 2021. Accessed March 15, 2022. https://www.abs.gov.au/statistics/people/people-and-communities/snapshot-australia/latest-release
- 22. Australian Government Department of Health and Aged Care. National Notifiable Disease Surveillance System. *Australian Government Department of Health and Aged Care*. Updated April 26, 2023. Accessed April 26, 2023. https://nindss.health.gov.au/pbi-dashboard/
- Lloyd M, Scott S. Doctors plead for help as respiratory infections rise in Australia, putting young children at risk. ABC News. July 12, 2022. Accessed April 26, 2023. https://www.abc.net.au/news/2022-07-12/respiratory-infections-rise-youngchildren/101210778

Table 1. Demographics of participants.

Characteristic	Category	Future Parent		Current Parent	
		N=	=61	N=1931	
		n	(%)	n	(%)
Age (years)	18-24	4	6.6%	37	1.9%
	25-39	52	85.2%	1673	86.6%
	40-59	5	8.2%	221	11.4%
Gender	Female	59	96.7%	1911	99.0%
	Male	1	1.6%	17	0.9%
	Non-binary	1	1.6%	3	0.2%
State	Northern Territory	1	1.6%	7	0.4%
	New South Wales	20	32.8%	535	27.7%
	Australian Capital Territory	1	1.6%	41	2.1%
	Victoria	12	19.7%	443	22.9%
	Queensland	8	13.1%	280	14.5%
	South Australia	1	1.6%	111	5.75%
	Western Australia	16	26.2%	477	24.7%
	Tasmania	2	3.3%	37	1.9%
Country of birth	Australia	45	73.8%	1492	77.3%
	Other than Australia	9	14.8%	257	13.3%
	No response	7	11.5%	182	9.4%
Indigenous Status	Non-Indigenous	54	88.5%	1720	89.1%
	Indigenous	0	0.0%	25	1.3%
	Prefer not to answer	0	0.0%	3	0.2%
	No response	7	11.5%	183	9.5%
Primary Language	English	51	83.6%	1644	85.1%
	Other than English	3	4.9%	100	5.2%
	No response	7	11.5%	187	9.7%
Highest Level of Education	University	46	75.4%	1318	68.3%
	TAFE/Apprenticeship	5	8.2%	257	13.3%
	High school	3	4.9%	151	7.8%
	Prefer not to answer	0	0.0%	12	0.6%
	Other	0	0.0%	10	0.5%
	No response	7	11.5%	183	9.5%
Employment Status	Full time/Part time	39	63.9%	943	48.9%
	Maternity leave	10	16.4%	550	28.5%
	Home duties	1	1.6%	216	11.2%
	Unemployed	0	0.0%	9	0.5%
	Student	2	3.3%	28	1.5%
	Prefer not to answer	2	3.3%	3	0.2%
	No response	7	11.5%	182	9.4%

Table 2. Participant awareness of respiratory illnesses and pathogens (N=1992).

Childhood Respiratory Condition	Response	Future Parent Subgroup N=61		Current Parent N=193	p-value	
		n	(%)	n	(%)	
Childhood Respiratory Pathogen:						
Influenza (the Flu)	Yes	58	95.1%	1835	95.0%	0.94
	No	0	0.0%	4	0.2%	
	No response	3	4.9%	92	4.8%	
Whooping cough	Yes	58	95.1%	1835	95.0%	0.94
	No	0	0.0%	4	0.2%	
	No response	3	4.9%	93	4.8%	
Chest infections	Yes	56	91.8%	1832	94.9%	0.18
	No	1	1.6%	6	0.3%	
	No response	4	6.6%	93	4.8%	
Pneumonia	Yes	56	91.8%	1826	94.6%	0.008
	No	2	3.3%	8	0.4%	
	No response	3	4.9%	97	5.0%	
Wheezing	Yes	52	85.2%	1770	91.7%	0.094
	No	5	8.2%	63	3.3%	
	No response	4	6.6%	98	5.1%	
Bronchiolitis	Yes	51	83.6%	1767	91.5%	0.025
	No	6	9.8%	66	3.4%	
	No response	4	6.6%	98	5.1%	
COVID-19	Yes	57	93.4%	1834	95.0%	0.80
	No	0	0.0%	3	0.2%	
	No response	4	6.6%	94	4.9%	
Common cold	Yes	58	95.1%	1833	94.9%	0.96
	No	0	0.0%	0	0.0%	
	No response	3	4.9%	98	5.1%	
Asthma	Yes	57	93.4%	1829	94.7%	0.84
	No	0	0.0%	3	0.2%	
	No response	4	6.6%	99	5.1%	
Ear infections	Yes	58	95.1%	1826	94.6%	0.86
	No	0	0.0%	0	0.0%	
	No response	3	4.9%	105	5.4%	
Childhood Respiratory Pathogen:	•					
Influenza virus	Yes	57	93.4%	1830	94.8%	0.30
	No	1	1.6%	7	0.4%	
	No response	3	4.9%	94	4.9%	
Bordetella pertussis	Yes	31	50.8%	1087	56.3%	0.48
•	No	27	44.3%	714	37.0%	
	No response	3	4.9%	130	6.7%	
Respiratory Syncytial Virus (RSV)	Yes	48	78.7%	1731	89.6%	<0.001
. , , ,	No	10	16.4%	97	5.0%	

	No response	3	4.9%	103	5.3%	
SARS-CoV-2	Yes	55	90.2%	1757	91.0%	0.94
	No	3	4.9%	78	4.0%	
	No response	3	4.9%	96	5.0%	
Rhinovirus	Yes	51	83.6%	1694	87.7%	0.32
	No	7	11.5%	127	6.6%	
	No response	7	11.5%	127	6.6%	

^{**}Subgroups used for analysis were the future parent subgroup (participants who do not currently have any young children) and the current parent subgroup (participants who do currently have young children).




Figure 1. Level of worry towards childhood respiratory illnesses in the future parent subgroup (A) and current parent subgroup (B). Note: excludes participants who did not respond. Participants were asked about how worried they would be if their young child were to contract such conditions. Conditions are listed in order of level of worry (from left to right).

Table 3. Factors associated with awareness of RSV.

Factors	Level	Univa	riate	Multiva	riate	
		OR (95% CI)	p-value	aOR (95% CI)	p-value	
Country of birth	Australia	7.17 (5.31, 9.69)	<0.001	2.47 (1.48, 4.12)	<0.001	
	Other than Australia	reference		reference		
Primary Language	English	9.55 (7.01, 13.01)	<0.001	1.37 (0.62, 3.05)	0.44	
	Other than English	reference		reference		
State	Northern Territory	reference		reference reference 6.15 (2.10, 18.04) NA 3.28 (1.17, 9.20) 6.64 (2.00, 21.99) 1.63 (0.52, 5.10) 1.78 (0.67, 4.72) NA reference 2.61 (1.38, 4.94)		
	New South Wales	2.82 (1.17, 6.78)	0.02	6.15 (2.10, 18.04)	<0.001	
	Australian Capital					
	Territory	8.97 (1.05, 76.66)	0.05	NA	NA	
	Victoria	1.66 (0.70, 3.95)	0.25	3.28 (1.17, 9.20)	0.02	
	Queensland	2.64 (1.05, 6.68)	0.04	6.64 (2.00, 21.99)	<0.002	
	South Australia	1.14 (0.44, 2.99)	0.79	1.63 (0.52, 5.10)	0.40	
	Western Australia	1.28 (0.54, 3.01)	0.57	1.78 (0.67, 4.72)	0.25	
	Tasmania	NA	NA	NA	NA	
Education Level	High School	reference		reference		
	University	2.11 (1.19, 3.73)	0.01	2.61 (1.38, 4.94)	<0.003	
	TAFE/apprenticeship or equivalent	1.26 (0.64, 2.49)	0.50	1.23 (0.59, 2.58)	0.58	
	Prefer not to answer	0.11 (0.06, 0.20)	<0.001	4.38 (0.09, 207.68)	0.45	
	Other	1.04 (0.12, 8.78)	0.97	0.44 (0.04, 4.63)	0.49	
Employment status	Full time/Part time	reference		reference		
	Maternity leave	0.60 (0.39, 0.92)	0.02	0.66 (0.41, 1.04)	0.08	
	Home duties	0.75 (0.40, 1.38)	0.35	0.98 (0.50, 1.92)	0.96	
	Unemployed	0.41 (0.05, 3.35)	0.41	1.15 (0.12, 12.27)	0.91	
	Student	0.72 (0.17, 3.12)	0.66	1.45 (0.18, 11.71)	0.73	
	Prefer not to answer	0.04 (0.03, 0.07)	<0.001	1.48 (0.03, 70.35)	0.84	
Subgroups	Future parent (no young children)	reference		reference		
	Current parent (young children)	2.34 (1.25, 4.40)	0.01	12.26 (2.82, 53.28)	<0.001	

Personal experience with RSV	Yes	8.02 (3.99, 16.12)	<0.001	6.66 (3.26, 13.64)	<0.001
	No	reference		reference	
	Unsure	1.28 (0.76, 2.15)	0.36	1.15 (0.66, 1.99)	0.63

^{**}All the variables depicted in Table 1 were entered into the model, however, were retained only if p≤0.2. Other variables that were entered into the model but not shown in Table 1, were subgroups (pregnancy only, young child), and whether participants who currently have young children had previous experience with their child contracting an RSV infection. Education level 'other' refers to participants who may be involved in Vocational Education and Training (VET), foundation courses, English courses or Business and Management Education etc.

OR = odds ratio

a OR = adjusted odds ratio

CI = confidence interval

NA = not able to be estimated




Figure 2. Amount parents were willing to pay for new RSV prevention strategies. Pregnant/planning parents were questioned on RSV maternal vaccines, and all parents (future and current) were questioned on RSV childhood immunisation. Participants were able to select any amount ranging from \$0-\$150. Note: excludes participants who did not respond.

Table 1. Awareness of conditions associated with RSV. Analysis includes only those participants who advised that they had heard of the virus before prior to completing the survey (N=1779).

Condition	Response	Future	Subgroup	Current	Current Subgroup		
		N:	=48	N=:	N=1731		
		n	(%)	n	(%)		
Influenza (the flu)	Yes	13	27.1%	434	25.1%	0.52	
	No	16	33.3%	641	37.0%		
	Unsure	12	25.0%	309	17.9%		
	Did not respond	7	14.6%	347	20.0%		
Whooping cough	Yes	4	8.3%	143	8.3%	0.47	
	No	26	54.2%	825	47.7%		
	Unsure	11	22.9%	340	19.6%		
	Did not respond	7	14.6%	423	24.4%		
Chest infection	Yes	28	58.3%	1188	68.6%	0.081	
	No	6	12.5%	139	8.0%		
	Unsure	12	25.0%	248	14.3%		
	Did not respond	2	4.2%	156	9.0%		
Pneumonia**	Yes	24	50.0%	1112	64.2%	0.009	
	No	7	14.6%	155	9.0%		
	Unsure	15	31.3%	278	16.1%		
	Did not respond	2	4.2%	186	10.7%		
Wheezing**	Yes	27	56.3%	1293	74.7%	0.003	
	No	7	14.6%	90	5.2%		
	Unsure	11	22.9%	214	12.4%		
	Did not respond	3	6.3%	134	7.7%		
Bronchiolitis**	Yes	25	52.1%	1242	71.8%	0.014	
	No	7	14.6%	114	6.6%		
	Unsure	13	27.1%	273	15.8%		
	Did not respond	3	6.3%	102	5.9%		
COVID-19	Yes	2	4.2%	125	7.2%	0.095	
	No	24	50.0%	882	51.0%		
	Unsure	14	29.2%	287	16.6%		
	Did not respond	8	16.7%	437	25.2%		

Common cold	Yes	18	37.5%	733	42.3%	0.14
	No	12	25.0%	471	27.2%	
	Unsure	13	27.1%	261	15.1%	
	Did not respond	5	10.4%	266	15.4%	
Asthma**	Yes	15	31.3%	530	30.6%	0.29
	No	15	31.3%	530	30.6%	
	Unsure	13	27.1%	343	19.8%	
	Did not respond	5	10.4%	359	20.7%	
Ear infections	Yes	8	16.7%	366	21.1%	0.16
	No	18	37.5%	621	35.9%	
	Unsure	16	33.3%	373	21.5%	
	Did not respond	6	12.5%	371	21.4%	
Gastroenteritis (gastro)	Yes	5	10.4%	93	5.4%	0.13
	No	23	47.9%	864	49.9%	
	Unsure	13	27.1%	337	19.5%	
	Did not respond	7	14.6%	437	25.2%	
Meningitis	Yes	6	12.5%	110	6.4%	0.13
	No	21	43.8%	796	46.0%	
	Unsure	14	29.2%	392	22.6%	
	Did not respond	7	14.6%	433	25.0%	

^{**} refers to conditions that are associated with RSV.